07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

BDL, Sorrento deal

In August, Sorrento’s TNK Therapeutics Inc. subsidiary purchased BDL for $100 plus $6 million in TNK stock. TNK gains two clinical-stage CAR-modified T cell immunotherapy programs in solid tumors and the underlying CAR-T technology. BDL...